The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
RNA Interference-directed Knockdown of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor Inhibits Prostate Cancer Cell Invasion, Survival, and Tumorigenicity in Vivo
Open accessAbstract
The invasive ability of tumor cells plays a key role in prostate cancer metastasis and is a major cause of treatment failure. Urokinase plasminogen activator-(uPA) and its receptor (uPAR)-mediated signaling have been implicated in tumor cell invasion, survival, and metastasis in a variety of cancers. This study was undertaken to investigate the biological roles of uPA and uPAR in prostate cancer cell invasion and survival, and the potential of uPA and uPAR as targets for prostate cancer therapy. uPA and uPAR expression correlates with the metastatic potential of prostate cancer cells. Thus, therapies designed to inhibit uPA and uPAR expression would be beneficial. LNCaP, DU145, and PC3 are prostate cancer cell lines with low, moderate, and high metastatic potential, respectively, as demonstrated by their capacity to invade the extracellular matrix. In this study we utilized small hairpin RNAs (shRNAs), also referred to as small interfering RNAs, to target human uPA and uPAR. These small interfering RNA constructs significantly inhibited uPA and uPAR expression at both the mRNA and protein levels in the highly metastatic prostate cancer cell line PC3. Our data demonstrated that uPA-uPAR knockdown in PC3 cells resulted in a dramatic reduction of tumor cell invasion as indicated by a Matrigel invasion assay. Furthermore, simultaneous silencing of the genes for uPA and uPAR using a single plasmid construct expressing shRNAs for both uPA and uPAR significantly reduced cell viability and ultimately resulted in the induction of apoptotic cell death. RNA interference for uPA and uPAR also abrogated uPA-uPAR signaling to downstream target molecules such as ERK1/2 and Stat 3. In addition, our results demonstrated that intratumoral injection with the plasmid construct expressing shRNAs for uPA and uPAR almost completely inhibited established tumor growth and survival in an orthotopic mouse prostate cancer model. These findings uncovered evidence of a complex signaling network operating downstream of uPA-uPAR that actively advances tumor cell invasion, proliferation, and survival of prostate cancer cells. Thus, RNA interference-directed targeting of uPA and uPAR is a convenient and novel tool for studying the biological role of the uPA-uPAR system and raises the potential of its application for prostate cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Lakka, S. S., Gondi, C. S., Yanamandra, N., Olivero, W. C., Dinh, D. H., Gujrati, M., & Rao, J. S. (2004) · Oncogene · doi:10.1038/sj.onc.1207616 · Cited by 291
Self-citationRetractedGondi, C. S., Lakka, S. S., Dinh, D. H., Olivero, W. C., Gujrati, M., & Rao, J. S. (2004) · Oncogene · doi:10.1038/sj.onc.1207879 · Cited by 141
Self-citationRetractedChandrasekar, N., Mohanam, S., Gujrati, M., Olivero, W. C., Dinh, D. H., & Rao, J. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206164 · Cited by 115
Self-citationRetractedGondi, C. S., Lakka, S. S., Yanamandra, N., Siddique, K., Dinh, D. H., Olivero, W. C., Gujrati, M., & Rao, J. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206535 · Cited by 94
Self-citationRetractedJemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
uPAR: a versatile signalling orchestrator
Blasi, F., & Carmeliet, P. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm977 · Cited by 1,223
Molecular mechanisms of glioma invasiveness: the role of proteases
Rao, J. S. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1121 · Cited by 847
Self-citationStat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue
Yuan, Z.-L., Guan, Y.-J., Chatterjee, D., & Chin, Y. E. (2005) · Science · doi:10.1126/science.1105166 · Cited by 790
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
Shah, R. B., Mehra, R., Chinnaiyan, A. M., Shen, R., Ghosh, D., Zhou, M., MacVicar, G. R., Varambally, S., Harwood, J., Bismar, T. A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2442 · Cited by 617
Naldini, L., Tamagnone, L., Vigna, E., Sachs, M., Hartmann, G., Birchmeier, W., Daikuhara, Y., Tsubouchi, H., Blasi, F., & Comoglio, P. M. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05588.x · Cited by 565
Ghiso, J. A. A., Kovalski, K., & Ossowski, L. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.147.1.89 · Cited by 549
Mora, L. B., Buettner, R., Seigne, J. D., Diaz, J. I., Ahmad, N., Garcia, R., Bowman, T. L., Falcone, R., Fairclough, R., Cantor, A. B., et al. (2002) · PubMed · Cited by 533
ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK)
Aguirre-Ghiso, J. A., Estrada, Y., Liu, D., & Ossowski, L. (2004) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2003.12.012 · Cited by 464
Assembly and function of RNA silencing complexes
Sontheimer, E. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1568 · Cited by 423
Resnati, M., Pallavicini, I., Wang, J. M., Oppenheim, J., Serhan, C. N., Romano, M., & Blasi, F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022652999 · Cited by 360
Zhang, Y., Zhang, Y.-F., Bryant, J., Charles, A., Boado, R. J., & Pardridge, W. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0740 · Cited by 330
Nguyen, D. H. D., Hussaini, I. M., & Gonias, S. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.14.8502 · Cited by 205
Laniado, M., Lalani, E., Fraser, S. P., Grimes, J. A., Bhangal, G., Djamgoz, M. B. A., & Abel, P. D. (1997) · Europe PMC (PubMed Central) · Cited by 201
Zhang, Z., Li, M., Wang, H., Agrawal, S., & Zhang, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934692100 · Cited by 192
Pakneshan, P., Szyf, M., Farias-Eisner, R., & Rabbani, S. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401669200 · Cited by 184
The Jak/Stat Pathway and Urokinase Receptor Signaling in Human Aortic Vascular Smooth Muscle Cells
Dumler, I., Weis, A., Mayboroda, O. A., Maasch, C., Jerke, U., Haller, H., & Gulba, D. C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.315 · Cited by 176
Stewart, D. A., Cooper, C. R., & Sikes, R. A. (2004) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-2-2 · Cited by 168
Zhang, X., Jin, T. J., Yang, H., DeWolf, W. C., Khosravi‐Far, R., & Olumi, A. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1498 · Cited by 164
Nguyen, D. H. D., Webb, D. J., Catling, A. D., Song, Q., Dhakephalkar, A., Weber, M. J., Ravichandran, K. S., & Gonias, S. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909575199 · Cited by 147
Schweinitz, A., Steinmetzer, T., Banke, I. G. J., Arlt, M., Stürzebecher, A., Schuster, O., Geissler, A., Giersiefen, H., Żesławska, E., Jacob, U., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314151200 · Cited by 129
uPA/Plasmin System-Mediated MMP-9 Activation Is Implicated in Bronchial Epithelial Cell Migration
Legrand, C., Polette, M., Tournier, J., et al. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5125 · Cited by 108
Kim, S. J., Uehara, H., Yazıcı, S., Langley, R. R., He, J., Tsan, R. Z., Fan, D., Killion, J. J., & Fidler, I. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3763 · Cited by 107
Pakneshan, P., Xing, R. H., & Rabbani, S. A. (2003) · The FASEB Journal · doi:10.1096/fj.02-0973com · Cited by 94
Expression and Functional Role of CCR9 in Prostate Cancer Cell Migration and Invasion
Singh, S., Singh, U. P., Stiles, J. K., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0266 · Cited by 94
Rabbani, S. A., & Gladu, J. (2002) · PubMed · Cited by 92
Jo, M., Thomas, K. S., Marozkina, N. V., Amin, T. J., Silva, C. M., Parsons, S. J., & Gonias, S. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413141200 · Cited by 90
Urokinase‐induced signaling in human vascular smooth muscle cells is mediated by PDGFR‐β
Kiyan, Y., Kiyan, R. V., Haller, H. G., & Dumler, I. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600669 · Cited by 86
Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes
Pinthus, J. H., Waks, T., Malina, V., Kaufman‐Francis, K., Harmelin, A., Aizenberg, I., Kanety, H., Ramon, J., & Eshhar, Z. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22284 · Cited by 86
Kim, S. J., Johnson, M., Koterba, K. L., Herynk, M. H., Uehara, H., & Gallick, G. E. (2003) · PubMed · Cited by 83
Dahiya, R., Park, H. D., Cusick, J., Vessella, R. L., Fournier, G. R., & Narayan, P. A. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590122 · Cited by 81
Ahmed, N., Oliva, K., Wang, Y., Quinn, M. A., & Rice, G. E. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601098 · Cited by 80
RNA Interference: Past, Present and Future
Choy, T. N. C. F. Y. M., & Choy, F. Y. M. (2005) · Current Issues in Molecular Biology · doi:10.21775/cimb.007.001 · Cited by 77
Regulation of STAT signalling by proteolytic processing
Hendry, L., & John, S. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04424.x · Cited by 74
Usher, P. A., Thomsen, O., Iversen, P., Johnsen, M., Brünner, N., Høyer‐Hansen, G., Andreasen, P. A., Danø, K., & Nielsen, B. S. (2004) · International Journal of Cancer · doi:10.1002/ijc.20665 · Cited by 74
Margheri, F., D’Alessio, S., Serratì, S., Pucci, M., Annunziato, F., Cosmi, L., Liotta, F., Angeli, R., Angelucci, A., Gravina, G. L., et al. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302456 · Cited by 71
Development of Irreversible Diphenyl Phosphonate Inhibitors for Urokinase Plasminogen Activator
Joossens, J., der Veken, P. V., Lambeir, A., Augustyns, K., & Haemers, A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0499209 · Cited by 66
Sato, S., Kopitz, C., Schmalix, W. A., Muehlenweg, B., Kessler, H., Schmitt, M., Krüger, A., & Magdolen, V. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03311-2 · Cited by 60
Keer, H. N., Gaylis, F. D., Kozlowski, J. M., Kwaan, H. C., Bauer, K. D., Sinha, A. A., & Wilson, M. J. (1991) · The Prostate · doi:10.1002/pros.2990180303 · Cited by 58
Mamoune, A., Kassis, J. N., Kharait, S., Kloeker, S., Manos, E., Jones, D. A., & Wells, A. H. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.05.008 · Cited by 52
Urokinase signal transduction and its role in cell migration
Carlin, S. M., Resink, T. J., Tamm, M., & Roth, M. (2005) · The FASEB Journal · doi:10.1096/fj.04-1644com · Cited by 44
Boyd, D. D., Kim, S.-J., Wang, H., Jones, T. R., & Gallick, G. E. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63855-2 · Cited by 43
Fabbrini, M. S., Carpani, D., Rivero, I. B., & Soria, M. R. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.13.9367352 · Cited by 42
D’Alessio, S., Margheri, F., Pucci, M., Rosso, A. D., Monia, B. P., Bologna, M., Leonetti, C., Scarsella, M., Zupi, G., Fibbi, G., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20077 · Cited by 41
Newer Therapies in Advanced Prostate Cancer
Hegeman, R. B., Liu, G., Wilding, G., & McNeel, D. G. (2004) · Clinical Prostate Cancer · doi:10.3816/cgc.2004.n.025 · Cited by 26
Interfering with Cancer: A Brief Outline of Advances in RNA Interference in Oncology
Rye, P. D., & Stigbrand, T. I. (2004) · Tumor Biology · doi:10.1159/000081403 · Cited by 24
The p38 SAPK pathway is required for Ha-ras induced in vitro invasion of NIH3T3 cells
Behren, A., Binder, K., Vucelic, G., Herberhold, S., Hirt, B., Löwenheim, H., Preyer, S., Zenner, H. P., & Simon, C. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.10.004 · Cited by 18
Is gene therapy the answer for prostate cancer?
Patel, P., Ashdown, D., & James, N. D. (2004) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500743 · Cited by 14
Cited by
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy
Ushio-Fukai, M., & Nakamura, Y. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.044 · Cited by 651
Giannoni, E., Bianchini, F., Masieri, L., Serni, S., Torre, E., Calorini, L., & Chiarugi, P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0785 · Cited by 596
Evolving role of uPA/uPAR system in human cancers
Dass, K., Ahmad, A., Azmi, A. S., Sarkar, S. H., & Sarkar, F. H. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.10.005 · Cited by 423
The urokinase plasminogen activator system: a target for anti-cancer therapy
Ulisse, S., Baldini, E., Sorrenti, S., & D'Armiento, M. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787314002 · Cited by 312
Metadata
- Authors
- Pulukuri, S. M., Gondi, C. S., Lakka, S. S., Jutla, A., Estes, N., Gujrati, M., & Rao, J. S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-10
- Volume
- 280
- Issue
- 43
- Pages
- 36529-36540
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1598733586
- Cited by
- 285
- References
- 52
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.